ACR and EULAR update 1981 criteria to reflect modern treatment options
Expression of CD154 Protein Linked to Increased Risk for Developing RA
An ongoing study of key immune system proteins has pinpointed an area associated with increased risk for inflammatory disease and may one day lead to new therapies to control inflammation and rheumatic diseases.
Chronotherapy with Glucorticoids in Rheumatoid Arthritis
Time is of the essence in balancing risks and benefits
Naturally Occurring Antibodies May Lead to New RA Therapies
A study published in the Journal of Immunology indicates that naturally occurring antibodies in the human immune system have the capacity to suppress inflammatory responses throughout the body. These antibodies may provide researchers an opportunity to develop new therapies for rheumatoid arthritis (RA) and other inflammatory conditions using similar pathways.
Immunizations and Autoimmune Disease
What is safe and what to avoid in this patient population
No Clear Connection Between Inflammation & Disease Progression in AS
TNF blockers decrease symptoms but seem to have little impact on structural damage
Research on IL-17 Cytokine May Lead to Novel Therapies for RA
Research in the laboratory of John D. Mountz, MD, PhD, is opening up a whole new field of study in rheumatoid arthritis (RA).
Are We Playing It Safe?
Tumor necrosis factor alpha inhibition and the risk of solid malignancies
Unique Meeting Accelerates RA Research
More than 50 rheumatoid arthritis (RA) investigators from across the U.S. recently met in Ft. Worth, Texas, to share information, present data and results from their innovative RA research projects, and brainstorm ways to work more closely together to find a cure for the disease.
REF’s Campaign to Support RA Research Nears its Initial Funding Target
The REF’s campaign to support RA research nears its initial funding target
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 75
- Next Page »